Add-on Acquisition • Healthcare Services

DiscernDx Acquires Luminist Labs

On April 29, 2020, DiscernDx acquired healthcare services company Luminist Labs

Acquisition Context
  • This is DiscernDx’s 1st transaction in the Healthcare Services sector.
  • This is DiscernDx’s 2nd transaction in the United States.
  • This is DiscernDx’s 2nd transaction in California.

Explore All 4611 Add-on Acquisition Healthcare Services Deals - Search the Database Free


M&A Deal Summary

Date April 29, 2020
Target Luminist Labs
Sector Healthcare Services
Buyer(s) DiscernDx
Deal Type Add-on Acquisition

Target Company

Luminist Labs

Newark, California, United States
Luminist Labs is a privately-held novel diagnostic platform company for the early detection and diagnosis of liver disease.
Explore More Deals

Browse All 215,156 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

DiscernDx

Palo Alto, California, United States

Category Company
Founded 2017
Sector Healthcare Services
DESCRIPTION

DiscernDx is a provider of precision medicine solutions that enables regular health monitoring, early disease detection, and personalized care for every individual, improving lives and transforming healthcare along the way. The company's mission is to empower everyone with access to individualized clinical and molecular data to proactively manage and make informed decisions about their health. DiscernDx was formed in 2017 and is based in Palo Alto, California.


Deal Context for Buyer #
Overall 2 of 2
Sector: Healthcare Services 1 of 1
Type: Add-on Acquisition 2 of 2
State: California 2 of 2
Country: United States 2 of 2
Year: 2020 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-02-08 Applied Proteomics

San Diego, California, United States

Applied Proteomics (API) is pioneering the best proteomics platform, a novel discovery approach to protein measurement-based diagnostics. API adopted an industrial approach to combine improved instrumentation, faster computing and extensive genome annotations with regimented standard operating procedures, extensive quality controls, and documented processes spanning hundreds of steps from sample collection to processing through informatics.

Buy $2M